An interventional study of PneuX Endotracheal Tube and Standard care (Taperguard, Covidien) in Ventilator Associated Pneumonia, Aspiration and Infections, sponsored by Cardiff and Vale University Health Board. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-25.
Sponsored by Cardiff and Vale University Health Board · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United Kingdom.
Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, this one is one of 2 that started in 2022, is one of 2 with no phase, and was the 9th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →2 of the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Cambridge · Sites in United Kingdom
Ages 1 mo–16 yrs
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 50 is below the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 182 across the 6 interventional studies, 250 across the 5 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
Cardiff and Vale University Health Board is the lead sponsor of 44 studies on the registry; 8 are open to participants now.
Cardiff and Vale University Health Board has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia, Ventilator-Associated with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT07026656University of CambridgePre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-associated Pneumonia in Critically Ill Children | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single centre, open-label, feasibility randomised controlled trial. The study aims to assess the feasibility of conducting an RCT to compare the PneuX ETT with standard care in hospitalised patients requiring mechanical ventilation. The patient population for this study are those who are experiencing critical illness requiring intubation and ventilatory support. Patients will be randomised in equal proportions into one of 2 arms: to be intubated using a Venner PneuX Endotracheal Tube (ETT) or using the standard tube. For this feasibility study, a total of 50 patients will be randomised into two groups (25 in each). All patients will be recruited at a single site (University Hospital of Wales, part of Cardiff \& Vale UHB). The study will investigate several feasibility measures including recruitment, delivery of the intervention (including device-related adverse events), acceptability and adherence to the intervention and sampling, use of Peptest to measure microaspiration events, rate of pepsin positive samples, rate of tracheobronchial colonisation, volume of sub-glottic aspirate, rate of VAP, length of ICU and hospital stay, demonstrate the validity of study documentation and provide preliminary data for 50 patients. The data will inform the pilot and main phase of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be intubated using the PneuX endotracheal tube system
Device: PneuX Endotracheal Tube
Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
Device: Standard care (Taperguard, Covidien)
The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
Also known as: Venner PneuX System
Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitment
The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described
Time frame: Through study completion, an average of 1 year
To assess the feasibility of delivering the study intervention
Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.
Time frame: Duration of study treatment (typically 4-7 days)
Number of participants with a failed pepsin test
Any issues such as failed sampling or failed testing will be recorded in case report form
Time frame: Duration of study treatment (typically 4-7 days)
Number of participants with a positive pepsin tracheal aspirate sample using Peptest
The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test
Time frame: Duration of study treatment (typically 4-7 days)
Volume of sub-glottic aspirates
The volume of the sub-glottic aspirates will be measured every 24 hours
Time frame: Duration of study treatment (typically 4-7 days)
Rate of tracheobronchial colonization
Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7
Time frame: Duration of study treatment (typically 4-7 days)
Proportion of patients who require antibiotics
The following will be assessed: antibiotic prescribed, indication for use, number of days administered
Time frame: 28 days
Rate of Ventilator Associated Pneumonia (VAP)
Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS \>6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation
Time frame: 28 days
Time spent on the ventilator
Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)
Time frame: Duration of study treatment (typically 4-7 days)
Number of days spent in ICU and hospital
Length of stay in ICU and length of stay in hospital measured in days from ventilation
Time frame: 28 days
Rate of in-hospital mortality
Number of patients who die in hospital up to 28 days after entry into ICU
Time frame: 28 days
Rate of compliance with measuring and documenting cuff pressure
Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.
Time frame: Duration of study treatment (typically 4-7 days)
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.
Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 24 months is above that.
Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
Cardiff and Vale University Health Board